Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.34 |
| ▸ | ITGAV | P06756 | 4/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | DNM2 | P50570 | 2/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.30 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22352723 | 0.81 | DRD4 (0.38) | CNR2CNR1SIRT2HDAC1HDAC2 | |
| SCHEMBL22354023 | 0.80 | ITGB3 (0.39) | CNR2CNR1ITGB3ITGAVITGA2B | |
| SCHEMBL22353628 | 0.79 | ITGB3 (0.35) | CNR2CNR1ITGB3ITGAVITGA2B | |
| SCHEMBL22354330 | 0.77 | ITGB3 (0.39) | CNR2CNR1ITGB3ITGAVITGA2B | |
| SCHEMBL24259317 | 0.76 | CNR2 (0.34) | CNR2CNR1SIRT2 | |
| SCHEMBL24259573 | 0.76 | ITGB3 (0.38) | CNR2CNR1ITGB3ITGAVITGA2B | |
| SCHEMBL22353002 | 0.76 | ABL1 (0.38) | CNR2CNR1SIRT2HDAC1HDAC2 | |
| SCHEMBL26686229 | 0.72 | DNM2 (0.50) | MEN1KMT2ADNM2HRH4 | |
| SCHEMBL24259637 | 0.70 | PRKAB2 (0.33) | MEN1KMT2AKDM4DHRH4 | |
| SCHEMBL16065138 | 0.70 | KDM4D (0.54) | MEN1KMT2AKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | CNR2 631/4885CNR1 325/4885ITGB3 2009/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | CNR2 631/4885CNR1 325/4885ITGB3 2009/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | CNR2 631/4885CNR1 325/4885ITGB3 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.